INSIGHTS ON ENTERPRISE SOLUTIONS

• What's The Real Challenge In Biologic Manufacturing Scale-up? It's Not Capacity — It's Demand

  As you plan your next stage of scale-up, take a moment to evaluate whether your manufacturing strategy is built around capacity — or around evolving market demand.

• Flexibility Or Scale? Navigating The Single Use Vs. Stainless Steel Debate

  Explore how to choose between single‑use and stainless‑steel bioreactors, outlining key advantages, limitations, and long‑term considerations essential for successful biologics scale‑up.

• Project Management: The Conductor Behind Every Successful CDMO Program

  Understand how elite CDMO project management acts as a conductor—integrating molecule expertise, rigorous readiness, and disciplined GMP execution to drive successful biologics manufacturing programs.

• The Future Of RNA Manufacturing Starts With Raw Material Innovation

  Amid the mRNA and oligonucleotide therapeutic boom, sponsors and manufacturers are exploring how to make critical raw materials—capping agents, lipid nanoparticles, and RNA polymerase—more effective.

• Preparing Pharma Operations For An Autonomous Future

  2/6/2026

  Biopharma’s push for faster delivery is accelerating a shift from automated to autonomous manufacturing. Explore how deeper connectivity and self‑optimizing systems are shaping the next frontier.

• Scaling Manufacturing Flexibility For Fill-Finish Commercial Success

  2/5/2026

  Pharma and biotech developers rely on adaptable fill‑finish capacity to meet evolving market demands, scale products from clinical to commercial, and respond rapidly to public‑health emergencies.

• Protecting Product Integrity Through Cold Chain

  2/5/2026

  Reliable temperature‑controlled storage, monitoring, and safeguards keep sensitive materials stable from fill to patient, protecting quality, preventing degradation, and ensuring safety throughout the cold chain.

• Smart Scaling For Cell And Gene Therapies

  2/5/2026

  To meet patient demand, advanced therapy manufacturing processes must be commercial ready. CGT sponsors can mitigate risk and protect viability by partnering with a CDMO that prioritizes scalability.